What development phase is Initiation of vasopressine as a first vasoconstrictive drug in?

Initiation of vasopressine as a first vasoconstrictive drug is FDA-approved (marketed).

Last reviewed 2026-05-14 · How we verify

Initiation of vasopressine as a first vasoconstrictive drug

University of Thessaly · FDA-approved active Small molecule Quality 0/100

Vasopressine, marketed by the University of Thessaly, is a first-line vasoconstrictive drug with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and first-mover advantage in vasoconstrictive therapy. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Initiation of vasopressine as a first vasoconstrictive drug
Also known as	Vasopressine, Empressin
Sponsor	University of Thessaly
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy of the Use of Vasopressin as a Primary Vasoconstrictor in Critically Ill Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Initiation of vasopressine as a first vasoconstrictive drug CI brief — competitive landscape report
Initiation of vasopressine as a first vasoconstrictive drug updates RSS · CI watch RSS
University of Thessaly portfolio CI